LLY vs. XOM: Eli Lilly vs. ExxonMobil Stock Comparison
How do Eli Lilly (LLY) and ExxonMobil (XOM) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas ExxonMobil (XOM) belongs to Energy (Energy) — their GICS classifications point to very different parts of the market.
| Profile Item | LLY | XOM |
|---|---|---|
| Name | Eli Lilly and Company | ExxonMobil Holdings Corporation |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Energy |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Energy |
| GICS Industry | Pharmaceuticals | Oil, Gas & Consumable Fuels |
| GICS Sub-Industry | Pharmaceuticals | Integrated Oil & Gas |
| Market Capitalization | 1,206.07 billion USD | 676.62 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 1, 1972 | January 2, 1962 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | LLY | XOM |
|---|---|---|
| Total Return (1Y) | 52.36% | 44.48% |
| Total Return (3Y, Annualized) | 34.18% | 20.83% |
| Total Return (5Y, Annualized) | 41.08% | 24.20% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | LLY | XOM |
|---|---|---|
| Volatility (1Y, Annualized) | 35.34% | 27.17% |
| Beta (5Y) | 0.40 | 0.19 |
| Max Drawdown (5Y) | -34.48% | -20.51% |
| Avg. Volume (3M) | 2.52M | 13.57M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | LLY | XOM |
|---|---|---|
| Sharpe Ratio (1Y) | 1.36 | 1.48 |
| Sortino Ratio (1Y) | 2.29 | 2.17 |
Profitability
ROE (TTM)
Eli Lilly (LLY) at 86.02% sits in the top ROE quartile, while ExxonMobil (XOM) at 15.53% is closer to the peer norm — stronger capital efficiency for LLY.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
86.02%
- Max
- 109.18%
- LLY
- 86.02%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
XOM
Energy industry group
15.53%
- Max
- 53.85%
- Q3
- 24.79%
- XOM
- 15.53%
- Median
- 12.85%
- Q1
- 2.03%
- Min
- -29.09%
Net Margin (TTM)
Eli Lilly (LLY) at 31.90% converts revenue to bottom-line profit above its industry’s benchmark range, while ExxonMobil (XOM) at 10.46% keeps roughly the typical share for its industry.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.90%
- LLY
- 31.90%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
XOM
Energy industry group
10.46%
- Max
- 56.92%
- Q3
- 22.92%
- XOM
- 10.46%
- Median
- 10.10%
- Q1
- 0.07%
- Min
- -27.38%
Operating Margin (TTM)
Eli Lilly (LLY) at 53.66% operates in the top operating margin quartile, ahead of ExxonMobil (XOM) at 16.98%, which runs around its industry’s norm.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
53.66%
- Max
- 83.12%
- LLY
- 53.66%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
XOM
Energy industry group
16.98%
- Max
- 71.31%
- Q3
- 33.75%
- Median
- 18.73%
- XOM
- 16.98%
- Q1
- 6.94%
- Min
- -24.52%
Profitability Metrics
| Metric | LLY | XOM |
|---|---|---|
| ROE (TTM) | 86.02% | 15.53% |
| ROA (TTM) | 21.06% | 6.75% |
| Net Margin (TTM) | 31.90% | 10.46% |
| Operating Margin (TTM) | 53.66% | 16.98% |
| Gross Margin (TTM) | 83.63% | 29.81% |
Growth
Revenue Growth
Both Eli Lilly (LLY) at 44.70% and ExxonMobil (XOM) at -4.52% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Eli Lilly (LLY) at 95.99% sits in the top EPS growth quartile, while ExxonMobil (XOM) at -14.54% is closer to the peer norm — faster per-share earnings growth for LLY.
Growth Metrics
| Metric | LLY | XOM |
|---|---|---|
| Revenue Growth (YoY) | 44.70% | -4.52% |
| Revenue Growth (3Y CAGR) | 31.69% | -6.69% |
| EPS Growth (YoY) | 95.99% | -14.54% |
| EPS Growth (3Y CAGR) | 51.71% | -20.35% |
Financial Strength
Current Ratio (MRQ)
ExxonMobil (XOM) at 1.19 keeps current ratio within its industry’s typical mid-range, while Eli Lilly (LLY) at 1.39 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for LLY.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- LLY
- 1.39
- Min
- 0.10
XOM
Energy industry group
1.19
- Max
- 3.64
- Q3
- 2.21
- Median
- 1.41
- XOM
- 1.19
- Q1
- 0.88
- Min
- 0.24
Debt / Equity (MRQ)
ExxonMobil (XOM) at 0.13 keeps leverage in the lower quartile, while Eli Lilly (LLY) at 1.23 sits in the higher-leverage quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.23
- Max
- 1.42
- LLY
- 1.23
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
XOM
Energy industry group
0.13
- Max
- 1.75
- Q3
- 0.93
- Median
- 0.54
- Q1
- 0.30
- XOM
- 0.13
- Min
- 0.00
Financial Strength Metrics
| Metric | LLY | XOM |
|---|---|---|
| Current Ratio (MRQ) | 1.39 | 1.19 |
| Debt / Equity (MRQ) | 1.23 | 0.13 |
| Net Debt / EBITDA | 0.96 | 0.28 |
Dividends
Dividend Yield (TTM)
ExxonMobil (XOM) at 2.49% pays an industry-typical yield; Eli Lilly (LLY) at 0.49% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.49%
- LLY
- 0.49%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
XOM
Energy industry group
2.49%
- Max
- 8.57%
- Q3
- 3.58%
- XOM
- 2.49%
- Median
- 1.71%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
ExxonMobil (XOM) at 42.39% keeps its payout in the industry’s typical band, while Eli Lilly (LLY) at 21.71% pays out more than any of its peers — the most stretched cover in its group.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
21.71%
- LLY
- 21.71%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
XOM
Energy industry group
42.39%
- Max
- 133.24%
- Q3
- 53.31%
- XOM
- 42.39%
- Median
- 25.24%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | LLY | XOM |
|---|---|---|
| Dividend Yield (TTM) | 0.49% | 2.49% |
| Dividend Payout Ratio (TTM) | 21.71% | 42.39% |
Valuation
P/E Ratio (TTM)
ExxonMobil (XOM) at 17.06 is near its industry’s usual P/E ratio, while Eli Lilly (LLY) at 43.95 sits in the richer quartile — LLY needs stronger growth or earnings quality to justify the premium.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
43.95
- Max
- 85.34
- LLY
- 43.95
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
XOM
Energy industry group
17.06
- Max
- 39.54
- Q3
- 21.72
- XOM
- 17.06
- Median
- 12.19
- Q1
- 7.71
- Min
- 2.99
P/S Ratio (TTM)
On P/S ratio, both Eli Lilly (LLY) at 13.95 and ExxonMobil (XOM) at 1.74 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.95
- Max
- 58.18
- Q3
- 25.77
- LLY
- 13.95
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
XOM
Energy industry group
1.74
- Max
- 5.40
- Q3
- 2.85
- XOM
- 1.74
- Median
- 1.69
- Q1
- 0.88
- Min
- 0.00
P/B Ratio (MRQ)
Both look rich against book: ExxonMobil (XOM) at 2.55 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 29.96 prices even higher, above its industry range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
29.96
- LLY
- 29.96
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
XOM
Energy industry group
2.55
- Max
- 4.21
- XOM
- 2.55
- Q3
- 2.38
- Median
- 1.51
- Q1
- 1.08
- Min
- 0.01
Valuation Metrics
| Metric | LLY | XOM |
|---|---|---|
| P/E Ratio (TTM) | 43.95 | 17.06 |
| P/S Ratio (TTM) | 13.95 | 1.74 |
| P/B Ratio (MRQ) | 29.96 | 2.55 |
| Free Cash Flow Yield (TTM) | 0.77% | 4.19% |